List view / Grid view
CE mark for Contivue platform supports its ambitions for Susvimo…
CE mark for Contivue platform supports its ambitions for Susvimo in age-related macular degeneration (AMD).
The BTK inhibitor enabled near-complete suppression of disability progression for…
The BTK inhibitor enabled near-complete suppression of disability progression for up to two years in individuals with relapsing multiple sclerosis (RMS), the new findings reveal.
The monoclonal antibody treatment is now approved in the US…
The monoclonal antibody treatment is now approved in the US for both diabetic macular oedema and wet, or neovascular age-related macular degeneration.
The new data highlights the potential of the ItovebiTM (inavolisib)-based…
The new data highlights the potential of the ItovebiTM (inavolisib)-based regimen as a new standard of care in advanced PIK3CA-mutated, HR-positive, HER2-negative breast cancer.
The new treatment option provides a convenient alternative to currently…
The new treatment option provides a convenient alternative to currently available vials of the bispecific antibody for EU patients with common vision conditions.
This article highlights some of the key regulatory approvals granted…
This article highlights some of the key regulatory approvals granted in May and June in the EU and US so far this year, including for oligonucleotide and biologic therapies.
The newly authorised formulation of the anti-CD20 therapy provides certain…
The newly authorised formulation of the anti-CD20 therapy provides certain multiple sclerosis patients with another treatment option comparable to intravenous infusion.
Spinal muscular atrophy (SMA) patients in the long-term extension Evrysdi…
Spinal muscular atrophy (SMA) patients in the long-term extension Evrysdi study maintained or improved key developmental skills over the five-year period, data shows.
The novel approval provides a dedicated therapy option for patients…
The novel approval provides a dedicated therapy option for patients with ALK-positive early-stage lung cancer.
EU approval for Roche’s subcutaneous OCREVUS is anticipated mid-2024, depending…
EU approval for Roche’s subcutaneous OCREVUS is anticipated mid-2024, depending on acceptance of regulatory submission.
The subcutaneous injection of the novel cancer immunotherapy Tecentriq® (atezolizumab)…
16 January 2024 | By
The subcutaneous injection of the novel cancer immunotherapy Tecentriq® (atezolizumab) could provide a quicker alternative to intravenous infusion, research shows.
The assets Roche will gain rights to through its planned…
The assets Roche will gain rights to through its planned acquisition of Carmot Therapeutics include several incretin treatments with best-in-class potential in obesity and diabetes.
If approved, Roche’s Tecentriq subcutaneous (SC) would be the EU’s…
If approved, Roche’s Tecentriq subcutaneous (SC) would be the EU’s first injectable PD-(L)1 cancer immunotherapy.
Roche is set to gain rights to develop, manufacture and…
Roche is set to gain rights to develop, manufacture and commercialise a novel antibody treatment with first-in-class and best-in-disease potential for inflammatory bowel disease (IBD), under a new acquisition agreement.
OCREVUS subcutaneous injection was comparable to intravenous (IV) infusion in…
OCREVUS subcutaneous injection was comparable to intravenous (IV) infusion in providing near-complete suppression of multiple sclerosis brain lesions over 24 weeks, Phase III study data shows.
